| |
Resistance
|
Association with antibiotic use
|
|---|
|
No. of tests/strata
|
Proportion resistant (95% CI)
|
Odds ratio (95% CI)
|
p-value
|
|---|
|
Amoxicillin-clavulanic acid
|
648 / 115
|
17 (14–21)
|
1.07 (1.01–1.14)
|
0.025
|
|
Ceftriaxone
|
369 / 92
|
10 (5–18)
|
1.12 (0.52–2.45)
|
0.77
|
|
Cefepime
|
369 / 92
|
3 (1–9)
|
0.86 (0.59–1.25)
|
0.43
|
|
Piperacillin-tazobactam
|
369 / 92
|
21 (17–25)
|
0.84 (0.61–1.18)
|
0.32
|
|
Quinolones
|
648 / 115
|
6 (3–9)
|
1.37 (0.94–2.01)
|
0.10
|
|
Trimethoprim-sulfamethoxazole
|
648 / 115
|
15 (12–19)
|
2.02 (1.44–2.84)
|
< 0.001
|
|
Gentamicin
|
369 / 92
|
8 (4–16)
|
1.82 (0.13–25.42)
|
0.66
|
|
Combined
|
3420 / 713
|
12 (8–16)
|
1.06 (0.99–1.14)
|
0.07
|
- Results from logistic mixed effects models. The odds ratios represent the relative change in the odds for resistance for an increase in antibiotic use by 5 DDD/100 bed-days. Strata refers to year/department combinations
- CI confidence interval
